Verastem's Commercial Inflection and RAS Pipeline Catalyst Set the Stage for a Busy H2

Q2 revenue rebound and VS-7375 progress highlight a pivotal quarter for the biotech.

VSTM · Earnings Call · 2026-08-06

Commercial Inflection

After a challenging start to the AVMAPKI FAKZYNJA CO-PACK launch, Verastem delivered a clear inflection point in Q2. Net product revenues came in at $25.1 million, and management reiterated that the franchise is on track to become self-sustaining by year-end. The rebound is driven by a combination of new patient starts, expanding physician adoption, and patients staying on therapy longer. As Dan Lyons noted, “We continue to see healthy and consistent levels of new patient starts and refills throughout the second quarter.” — Daniel Lyons, Senior Vice President, Commercial · 2026-08-06 This marks a departure from the earlier launch, where heavy pre-treatment and short durations had weighed on growth. The company's focus on moving patients to earlier lines of therapy is paying off. Management cited meaningful growth in new accounts and a shift toward first or next recurrence. This is critical, as earlier-line patients tend to mirror the RAMP-201 trial population with better outcomes. The new patient starts momentum is supported by a reimagined DTP/patient campaign and site-specific alerts in the community. Prior to the quarter, management had already signaled a rebound: “I will say with confidence, we already are sure that we will see an increase from Q1 to Q2 that was bigger than the Q4 to Q1.” — Daniel Paterson, Chief Executive Officer · 2026-05-07

VS-7375: The Next Catalyst

The bigger opportunity remains VS-7375, a KRAS G12D inhibitor. The company initiated three Phase II registration-directed trials across pancreatic, colorectal, and NSCLC, and will present a comprehensive data update in October, including response rates across the three tumor types. Management believes the drug can be best-in-class, citing its favorable tolerability profile and dose-dependent PK. CEO Dan Paterson asserted, “We intend to show better efficacy and significantly better tolerability” — Daniel Paterson, Chief Executive Officer · 2026-08-06 against panRAS inhibitors. The G12D inhibitor space is heating up with competitor data, but Verastem's focus on tolerability and combination potential sets it apart. The accelerated approvals pathway is a key part of the strategy, and the company has aligned with FDA feedback on the design. With completed enrollment in the Phase I expansion cohorts and fast-track designation for NSCLC, the program is on a rapid trajectory. In May, the company acknowledged the need for U.S. data: “We need U.S. data, and we need a lot of detail on the patients and their prior therapy, and we're quite optimistic that we'll be able to deliver on that.” — Eric Schmidt, Analyst · 2026-05-07

Balance Sheet Flexibility

The company strengthened its balance sheet with a $50 million draw from a non-dilutive Oberland Capital facility and a $15 million milestone from Secura Bio. Pro forma cash stands at $201.4 million, extending runway into H2 2027. This removes immediate dilution pressure and provides strategic flexibility for partnership discussions. As CFO Dan Calkins stated, “We believe we have sufficient capital to fund operations into the second half of 2027 and reach meaningful value-creating inflection points before needing to access additional capital.” — Daniel Calkins, Chief Financial Officer · 2026-08-06 This is a marked change from prior quarters where the company signaled a need for financing. The line of therapy shift and commercial momentum give management confidence to avoid distressed capital raises. The latest reported quarter (Q1 2026) showed total revenue of $19 million, with the trend turning upward, and Q2 came in even higher at $25.1 million.

What to Watch

The focus for H2 is clear: drive CO-PACK adoption, complete Phase II enrollment, and prepare for Phase III trials. The October data will be a major catalyst. If response rates meet the ~30% ORR and 6-month durability bar, the stock could re-rate significantly. The recent price action (+29.8% over the last 90 days) suggests investors are positioning for this event. Given the company's small market cap ($362M), a positive readout could be transformative. However, the crowded G12D landscape means differentiation on safety and efficacy will be critical.

We delivered a strong second quarter with meaningful progress across both our commercial business and pipeline.
Daniel Paterson, Chief Executive Officer · 2026-08-06